Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of ciclosporin (also known as cyclosporine), a calcineurin inhibitor immunosuppressant, and a corticosteroid (such as prednisolone or prednisone). Ciclosporin acts primarily by inhibiting calcineurin, thereby suppressing T-cell activation and reducing immune-mediated inflammation. Corticosteroids are anti-inflammatory agents that modulate gene expression to broadly suppress immune responses. The combination is used in clinical practice for conditions requiring potent immunosuppression, such as organ transplantation (to prevent rejection) and certain autoimmune or inflammatory diseases like idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. This regimen leverages the synergistic effects of both drugs to achieve better disease control than either agent alone[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciclosporin + corticosteroid.